ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,201.54
-0.28%
Dow Jones
42,236.23
-0.14%
Gold vs US Dollar
2,668.845
0.02%
Brent Oil
79.845
-0.54%
Bitcoin
95,852.36
1.42%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biomea Fusion Inc (BMEA)

  7. Biomea Fusion Inc (BMEA) News

Biomea Fusion (BMEA)

Biomea Fusion Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BMEA
DateTimeSourceHeadlineSymbolCompany
13/01/202514:00GlobeNewswire Inc.Biomea Fusion to Become a Diabetes & Obesity Medicines CompanyNASDAQ:BMEABiomea Fusion Inc
07/01/202514:00GlobeNewswire Inc.Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination StudyNASDAQ:BMEABiomea Fusion Inc
06/01/202521:57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
06/01/202512:00GlobeNewswire Inc.Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
20/12/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
17/12/202413:10GlobeNewswire Inc.Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
16/12/202423:15GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)NASDAQ:BMEABiomea Fusion Inc
12/12/202422:02GlobeNewswire Inc.Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)NASDAQ:BMEABiomea Fusion Inc
09/12/202421:01GlobeNewswire Inc.Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
06/12/202413:00GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
02/12/202421:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
18/11/202413:00GlobeNewswire Inc.Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
01/11/202420:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
31/10/202410:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
30/10/202420:00GlobeNewswire Inc.Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateNASDAQ:BMEABiomea Fusion Inc
29/10/202421:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
29/10/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
29/10/202420:46GlobeNewswire Inc.Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
21/10/202413:00GlobeNewswire Inc.Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219NASDAQ:BMEABiomea Fusion Inc
15/10/202420:05GlobeNewswire Inc.Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RNASDAQ:BMEABiomea Fusion Inc
07/10/202413:00GlobeNewswire Inc.Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
01/10/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
01/10/202413:00GlobeNewswire Inc.Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsNASDAQ:BMEABiomea Fusion Inc
27/09/202420:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
26/09/202418:00GlobeNewswire Inc.FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes TrialsNASDAQ:BMEABiomea Fusion Inc
01/08/202420:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
31/07/202420:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
31/07/202420:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
31/07/202420:05GlobeNewswire Inc.Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
13/06/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
 Showing the most relevant articles for your search:NASDAQ:BMEA

Your Recent History

LSE
CARD
Card Factory
LSE
SYME
Supply@me Capital
LSE
SCLP
Scancell
LSE
BOO
Boohoo
LSE
JD.
Jd Sports Fashion
LSE
TW.
Taylor Wimpey
LSE
TRLS
Trellus Health
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
GLEN
Glencore
LSE
AAZ
Anglo Asian Mining
LSE
TERN
Tern
LSE
GEX
Georgina Energy
LSE
POS
Plexus
LSE
JLP
Jubilee Metals
LSE
PANR
Pantheon Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads